- When used in combination with disease-modifying antirheumatic drugs (DMARDs) or as monotherapy, the recommended starting dose of ACTEMRA for adult patients who have had an inadequate response to one or more DMARD antagonists is 4 mg/kg followed by an increase to 8 mg/kg based on clinical response
- ACTEMRA should be given once every 4 weeks as a 60-minute single intravenous drip infusion
- Patients treated with ACTEMRA 8 mg/kg showed higher response rates than patients treated with
ACTEMRA 4 mg/kg
- Doses exceeding 800 mg per infusion are not recommended
- ACTEMRA must not be used in combination with biologic DMARDs because of the possibility of increased immunosuppression and increased risk of infection
- Reduction of dose from 8 mg/kg to 4 mg/kg is recommended for management of certain dose-related laboratory changes including elevated liver enzymes, neutropenia and thrombocytopenia
What type of patient are you treating?
Enter patient weight to determine dose option and calculate dose.
Recommended SJIA dosage every 2 weeks
|Patients < 30 kg||12 mg/kg|
|Patients ≥ 30kg||8 mg/kg|
Page will refresh after 5 minutes.
By using this resource, you agree to the following: This Dosing Calculator is being provided “AS IS” and is intended for use only by qualified healthcare providers. All calculations should be confirmed before use. Genentech makes no claims as to the accuracy of the information contained herein. The information being provided is not a substitute for clinical judgment. Neither Genentech, nor any other party involved in the preparation or publication of this site shall be liable to you or others for any decisions made or actions taken by you or others in reliance on this information.
- ACTEMRA should not be infused concomitantly in the same intravenous line with other drugs.
- ACTEMRA must be administered with an infusion set.
- Do not administer as an intravenous push or bolus.
- Dosing Calculator should not replace professional judgment or clinical experience.
For additional dosing information please refer to the Dosing Guide.
- Doses exceeding 800 mg per infusion are not recommended.
- Dosing Calculator is not a substitute for medical examination. Please see Dosing Guide for more information.
ACTEMRA may be used as monotherapy or concomitantly with methotrexate or other DMARDs. The recommended dose of ACTEMRA for adult patients given once every 4 weeks as a 60-minute single intravenous drip infusion is:
Recommended Adult Dosage Every 4 Weeks
Patients who have had an inadequate response to one or more TNF antagonists
When used in combination with DMARDs or as monotherapy the recommended starting dose is 4 mg per kg followed by an increase to 8 mg per kg based on clinical response.
- Reduction of dose from 8 mg per kg to 4 mg per kg is recommended for management of certain dose-related laboratory changes including elevated liver enzymes, neutropenia, and thrombocytopenia.
- Doses exceeding 800 mg per infusion are not recommended in RA patients
Systemic Juvenile Idiopathic Arthritis
ACTEMRA may be used alone or in combination with methotrexate. The recommended dose of ACTEMRA for SJIA patients given once every 2 weeks as a 60-minute single intravenous drip infusion is:
Recommended SJIA Dosage Every 2 Weeks
Patients less than 30 kg weight
12 mg per kg
Patients at or above 30 kg weight
8 mg per kg
- A change in dose should not be made based solely on a single visit body weight measurement, as weight may fluctuate.
- Interruption of dosing may be needed for management of dose-related laboratory abnormalities including elevated liver enzymes, neutropenia, and thrombocytopenia.
- ACTEMRA has not been studied and its use should be avoided in combination with biological DMARDs such as TNF antagonists, IL-1R antagonists, anti-CD20 monoclonal antibodies and selective co-stimulation modulators because of the possibility of increased immunosuppression and increased risk of infection.
- It is recommended that ACTEMRA not be initiated in patients with an absolute neutrophil count (ANC) below 2000 per mm3, platelet count below 100,000 per mm3, or who have ALT or AST above 1.5 times the upper limit of normal (ULN).
Please see full Prescribing Information including Boxed Warning for additional important safety information.